WebmedCentral Editor
View all WebmedCentral Editors
No Image

Dr. Cornel Pater

Sr. Consultant Cardiologist/Medical Director
Med Aff/Elan
Moertvagen 23

Brief Biography:

Educational background

1. Internal Medicine - Board certified 13 May 1991 (Swedish Board of Health and Welfare)
2. Cardiology - Board certified 30 March 1992 (Swedish Board of Health and Welfare)
3. GMC - General Medical Council, UK - full registration as specialist Internal Medicine and  
Cardiology (Reg. Nr. 4498519 - April 1998)

Postgraduate training

1. MSc degree - Master of Science in Clinical Epidemiology and Biostatistics, Erasmus University Rotterdam, the Netherlands, June 1998
2. MPH degree - Master of Public Health, NSPH, Utrecht, the Netherlands, June 2001


Academic positions:

Professional background

1. 1987 - 1992 – Specialist Registrar/Clinician/Clinical Investigator
2. 1992 - 1999 - Head of Cardiology Division, Internal Medicine Department, Hassleholms Hospital Sweden
3. 1999 - 2000 - Consultant Cardiologist and Project Director (Cardiovascular) -University Hospital Akershus, Oslo, Norway
4. 2001 - 2002 - Senior Clinical Research Physician - Cardiology – Quantum Research Ltd., UK
Welwyn Garden City, UK.
5. 2002 - 2005 - Global Director of Clinical Research, Cardiovascular Clinical Development,  
Solvay Pharmaceuticals, Hannover, Germany
6. 2005 - 2008 - Senior Medical Director/CMO, International - Omnicare Clinical Research,
Chippenham, UK
7. 2008 - 2011 -  Medical Director Scandinavia & UK, Elan Pharma International Ltd.
8. 2012 - Sr. Consultant Cardiologist, Global Medical Director, Medical Affairs–Novartis AG, Basel, Switzerland


Research interests:

- Extensive experience with large hypertension/diabetes trials and fixed-combination products (drug/drug, drug/device)
- Oversight of drug/medical device development programs from discovery/inception stages to submission of NDA (familiar with both EMEA and FDA requirements) along with planning, design,  
implementation and assessment of effectiveness of Risk Management programs during drug/device development
- Comprehensive project management as required in phase II-III of clinical development (planning, study design, conduct, analysis and reporting).  
- Expertise in project management adjusted to early- and late-phase clinical trials (phase IV) to match marketing strategy needs during drug `s/device`s life cycle and specific regulatory requirements (post-approval surveillance and epidemiologic studies).


What I think of the idea behind WebmedCentral: